Cargando…

Sofosbuvir‐based regimens for the treatment of chronic hepatitis C in severe renal dysfunction

Sofosbuvir (SOF) is a nonstructural 5B polymerase inhibitor with activity in all hepatitis C virus (HCV) genotypes and is the backbone of many anti‐HCV drug regimens. SOF is converted into inactive metabolites that undergo renal excretion. Patients with an estimated glomerular filtration rate (eGFR)...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cox‐North, Paula, Hawkins, Kelsey L., Rossiter, Sean T., Hawley, Marie N., Bhattacharya, Renuka, Landis, Charles S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2017
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5721450/ https://www.ncbi.nlm.nih.gov/pubmed/29404457 http://dx.doi.org/10.1002/hep4.1035

Ejemplares similares

Incidence of Hepatocellular Carcinoma after Treatment with Sofosbuvir-Based or Sofosbuvir-Free Regimens in Patients with Chronic Hepatitis C
por: Ogawa, Eiichi, et al.
Publicado: (2020)

Changes in renal function indices in cirrhotic chronic hepatitis C patients treated with sofosbuvir-containing regimens
por: Chen, Jianhong, et al.
Publicado: (2017)

Sofosbuvir and Velpatasvir Regimen Outcome for Chronic Hepatitis C Patients With End-Stage Renal Disease Undergoing Hemodialysis
por: Shahid, Salman, et al.
Publicado: (2023)

Hemodialysis Patients Treated for Hepatitis C Using a Sofosbuvir-based Regimen
por: Agarwal, Sanjay Kumar, et al.
Publicado: (2017)

Sofosbuvir/velpatasvir regimen promises an effective pan-genotypic hepatitis C virus cure
por: Mir, Fazia, et al.
Publicado: (2017)

Treatment Outcomes for Patients Undergoing Hemodialysis with Chronic Hepatitis C on the Sofosbuvir and Daclatasvir Regimen
por: Butt, Nazish, et al.
Publicado: (2019)

Clinical and economic value of sofosbuvir-based regimens in the treatment of chronic hepatitis C in Spain
por: Esteban, Rafael, et al.
Publicado: (2022)

Efficacy and safety of sofosbuvir-based regimens for treatment in chronic hepatitis C genotype 1 patients with moderately impaired renal function
por: Shin, Hyun Phil, et al.
Publicado: (2017)

Fulminant hepatitis B reactivation leading to liver transplantation in a patient with chronic hepatitis C treated with simeprevir and sofosbuvir: a case report
por: Ende, Alexander R., et al.
Publicado: (2015)

Cost-utility analysis of four WHO-recommended sofosbuvir-based regimens for the treatment of chronic hepatitis C in sub-Saharan Africa
por: Boyer, Sylvie, et al.
Publicado: (2022)

Sofosbuvir Based Regimens in the Treatment of Chronic Hepatitis C with Compensated Liver Cirrhosis in Community Care Setting
por: Gayam, Vijay, et al.
Publicado: (2018)

Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post‐liver transplantation recurrence
por: Poordad, Fred, et al.
Publicado: (2016)

Sofosbuvir/velpatasvir/voxilaprevir for hepatitis C
Publicado: (2019)

Sofosbuvir-based Regimens with Task Shifting Is Cost-effective in Expanding Hepatitis C Treatment Access in the United States
por: Jayasekera, Channa R., et al.
Publicado: (2017)

Sofosbuvir-based regimens in the treatment of patients with chronic hepatitis C virus infection: Real-world efficacy in Thailand
por: Sirinawasatien, Apichet, et al.
Publicado: (2020)

Effect of Health Insurance on Hepatitis C Sustained Virologic Response Rates to Sofosbuvir-Based Treatment Regimens in a South Florida Community Hospital
por: Eckardt, Paula, et al.
Publicado: (2019)

Efficacy and Safety of Sofosbuvir/Velpatasvir Plus Ribavirin in Patients with Hepatitis C Virus-Related Decompensated Cirrhosis
por: Flamm, Steven, et al.
Publicado: (2023)

Real-World Single-Center Experience with Sofosbuvir-Based Regimens for the Treatment of Chronic Hepatitis C Genotype 1 Patients
por: Shin, Hyun Phil, et al.
Publicado: (2017)

Outcomes after sofosbuvir-containing regimens for hepatitis C virus in patients with decompensated cirrhosis: a real-world study
por: Ji, Fanpu, et al.
Publicado: (2017)

Efficacy and Safety of Sofosbuvir-based Regimens in Hepatitis C Patients With Decompensated Cirrhosis: A Systematic Review and Meta-analysis
por: Zhang, Wenyan, et al.
Publicado: (2023)

The Efficacy and Safety of Sofosbuvir-Containing Regimen in the Treatment of HCV Infection in Patients with Haemoglobinopathy
por: Hussein, N.R.
Publicado: (2017)

Sofosbuvir/Velpatasvir/Voxilaprevir for patients with HCV who previously received a Sofosbuvir/Velpatasvir‐containing regimen: Results from a retreatment study
por: Ruane, Peter, et al.
Publicado: (2019)

Comparative Antiviral Efficacy of Generic Sofosbuvir versus Brand Name Sofosbuvir with Ribavirin for the Treatment of Hepatitis C
por: Tang, L., et al.
Publicado: (2018)

Cost-Effectiveness Analysis of Pan-Genotypic Sofosbuvir-Based Regimens for Treatment of Chronic Hepatitis C Genotype 1 Infection in China
por: Zhou, Hui Jun, et al.
Publicado: (2021)

Safety and efficacy of sofosbuvir‐based medication regimens with and without ribavirin in hepatitis C patients: A systematic review and meta‐analysis
por: Elshafie, Shaimaa, et al.
Publicado: (2022)

Three regimens for re-treatment failure of Sofosbuvir-based therapy for chronic hepatitis-C genotype-4: a cohort study
por: Shousha, Hend Ibrahim, et al.
Publicado: (2022)

Estimating the cost-effectiveness of daclatasvir + sofosbuvir versus sofosbuvir + ribavirin for patients with genotype 3 hepatitis C virus
por: McEwan, Phil, et al.
Publicado: (2017)

Sofosbuvir–velpatasvir and sofosbuvir–velpatasvir–voxilaprevir: novel treatment options for naïve and previously treated hepatitis C infection
por: Shin, Hyun Phil
Publicado: (2023)

Cost-effectiveness of sofosbuvir in the treatment of patients with hepatitis C
por: Leleu, H, et al.
Publicado: (2015)

Profile of sofosbuvir/velpatasvir/voxilaprevir in the treatment of hepatitis C
por: Childs-Kean, Lindsey M, et al.
Publicado: (2019)

Sofosbuvir/Velpatasvir for the treatment of Hepatitis C Virus infection
por: Anna, Linda Zignego, et al.
Publicado: (2018)

Interferon-free regimens in patients with hepatitis C infection and renal dysfunction or kidney transplantation
por: Cholongitas, Evangelos, et al.
Publicado: (2017)

Efficacy and safety of sofosbuvir-containing regimens in patients with chronic hepatitis C virus infection after liver transplantation: a meta-analysis
por: Fu, Hua, et al.
Publicado: (2020)

Real‐world treatment outcomes of sofosbuvir‐based regimens for treatment of chronic hepatitis C with and without human immunodeficiency virus co‐infection
por: Khemnark, Suparat, et al.
Publicado: (2023)

Real-world effectiveness and safety of sofosbuvir/velpatasvir and ledipasvir/sofosbuvir hepatitis C treatment in a single centre in Germany
por: Buggisch, Peter, et al.
Publicado: (2019)

Efficacy and safety of sofosbuvir–velpatasvir and sofosbuvir–velpatasvir–voxilaprevir for hepatitis C in Korea: a Phase 3b study
por: Heo, Jeong, et al.
Publicado: (2023)

Use of sofosbuvir based regimen in patients with end-stage renal disease and chronic hepatitis C; an open label, non-randomized, single arm, single center study from Pakistan
por: Mandhwani, Rajesh, et al.
Publicado: (2020)

Sofosbuvir and daclatasvir
por: Hessel, Marleen H. M., et al.
Publicado: (2016)

HIV/HCV therapy with ledipasvir/sofosbuvir after randomized switch to emtricitabine-tenofovir alafenamide-based single-tablet regimens
por: Huhn, Gregory D., et al.
Publicado: (2020)

Health utilities using SF-6D scores in Japanese patients with chronic hepatitis C treated with sofosbuvir-based regimens in clinical trials
por: Younossi, Zobair, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_geboam5vimqsglig05apt5po68